Literature DB >> 29096746

Overexpression of microRNA-133b reduces myocardial injuries in children with viral myocarditis by targeting Rab27B gene.

Y Zhang1, L Sun1, H Sun2, X Liu2, X Luo2, C Li2, D Sun1, T Li2.   

Abstract

The present study is to measure the expression of microRNA (miRNA or miR)-133b in circulating blood of children with viral myocarditis before and after drug treatment, and to investigate its relationship with the severity of myocardial lesions. A total of 36 children patients with viral myocarditis who received treatments at our hospital between June 2014 and June 2016 were enrolled in the present study, including 21 boys and 15 girls (age range, 9 months - 16 years).Quantitative real-time polymerase chain reaction was used to determine the expression of miR-133b in peripheral blood of patients and cardiomyocytes infected with CVB3. CCK-8 assay was used to test the proliferation of cardiomyocytes. ELISA was used to determine the levels of creatine kinase (CK-MB) and lactate dehydrogenase (LDH) in peripheral blood and cardiomyocyte culture supernatants. Western blotting and ELISA were performed to measure the levels of tumor necrosis factor-α and interleukin-6 in cardiomyocytes infected by CVB3 and cell culture supernatants. Bioinformatics was used to predict the target gene of miR-133b. Silencing of Rab27B gene was achieved by transfection with its small-interfering RNA. Dual luciferase reporter assay was carried out to test whether miR-133b directly targets Rab27B. Reduced expression of miR-133b in peripheral blood was possibly correlated with myocardial injuries in viral myocarditis miR-133b. Expression of miR-133b was significantly reduced in cardiomyocytes infected with CVB3 virus. Overexpression of miR-133b inhibited cardiomyocyte injuries caused by CVB3 virus infection, and the enhanced production and release of cytokines TNF-α and IL-6 by cardiomyocytes infected with CVB3 virus. Rab27B promoted injuries of cardiomyocytes induced by CVB3 infection and facilitated the synthesis and release of cytokines TNF-α and IL-6 by cardiomyocytes. miR-133b was able to bind to the 3'-untranslated region seeding region of Rab27B mRNA. The present study demonstrates that expression of miR-133b in peripheral blood from children with viral myocarditis is reduced, and negatively correlated with myocardial injuries. miR-133b inhibits the proliferation of cardiomyocytes and the release of cytokines TNF-α and IL-6, and alleviates CVB3 infection-induced myocardial injuries by targeting Rab27B.

Entities:  

Keywords:  Myocardial injury; Rab27B.; Viral myocarditis; miR-133b

Mesh:

Substances:

Year:  2017        PMID: 29096746     DOI: 10.14715/cmb/2017.63.10.13

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  5 in total

Review 1.  Picornaviruses and RNA Metabolism: Local and Global Effects of Infection.

Authors:  Autumn C Holmes; Bert L Semler
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

Review 2.  The role of non-coding RNAs in myocarditis: a narrative review.

Authors:  Wenhu Liu; Jing Hu; Shuai Lu; Zhaohui Wang
Journal:  Ann Transl Med       Date:  2022-09

3.  MicroRNA‑133b alleviates doxorubicin‑induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2.

Authors:  Zhen Li; Zekang Ye; Jiazheng Ma; Qian Gu; Jianzhen Teng; Xiaoxuan Gong
Journal:  Int J Mol Med       Date:  2021-05-13       Impact factor: 4.101

4.  Exosome-transmitted microRNA-133b inhibited bladder cancer proliferation by upregulating dual-specificity protein phosphatase 1.

Authors:  Xiaoxiao Cai; Lili Qu; Jian Yang; Junwen Xu; Li Sun; Xiaowei Wei; Xiaojun Qu; Tingting Bai; Zhirui Guo; Yefei Zhu
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

Review 5.  The Role of Non-coding RNAs in Viral Myocarditis.

Authors:  Cong Zhang; Yan Xiong; Lijin Zeng; Zhihua Peng; Zhihao Liu; Hong Zhan; Zhen Yang
Journal:  Front Cell Infect Microbiol       Date:  2020-07-02       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.